Financial Performance - The company's revenue for Q1 2024 was CNY 807,154,893.30, a decrease of 5.64% compared to CNY 855,367,818.78 in the same period last year[5] - Net profit attributable to shareholders was CNY 101,221,564.63, down 24.75% from CNY 134,514,033.42 year-on-year[5] - Basic earnings per share decreased to CNY 0.5, down 23.08% from CNY 0.65 in the same period last year[5] - Operating profit for Q1 2024 was CNY 119.28 million, down 24.25% from CNY 157.56 million in Q1 2023[25] - Net profit attributable to the parent company for Q1 2024 was CNY 101.22 million, a decrease of 24.73% compared to CNY 134.51 million in Q1 2023[25] - The company reported a total comprehensive income of CNY 101.04 million for Q1 2024, compared to CNY 133.37 million in Q1 2023, a decline of 24.14%[25] Cash Flow - The net cash flow from operating activities increased by 48.30% to CNY 228,412,107.91, compared to CNY 154,022,832.30 in the previous year[5] - The net cash flow from financing activities improved by 167.03%, reaching CNY 59,573,972.94, compared to a negative cash flow in the previous year[12] - Total cash inflow from operating activities was ¥838,733,918.37, down 16.7% from ¥1,007,074,809.83 in the previous period[28] - Cash outflow from operating activities decreased to ¥610,321,810.46, a reduction of 28.5% from ¥853,051,977.53 in the previous period[28] - The net cash flow from investing activities was -¥70,879,417.49, an improvement from -¥115,099,925.82 in the previous period[28] - Cash inflow from financing activities increased to ¥339,669,662.71, compared to ¥324,926,529.88 in the previous period[28] - The ending balance of cash and cash equivalents was ¥1,658,375,915.70, up from ¥1,320,497,604.99 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,455,639,642.73, reflecting a 3.39% increase from CNY 6,244,191,736.83 at the end of the previous year[5] - Total assets increased to CNY 6.46 billion in Q1 2024 from CNY 6.24 billion in Q1 2023, reflecting a growth of 3.39%[22] - Total liabilities rose to CNY 1.47 billion in Q1 2024, compared to CNY 1.34 billion in Q1 2023, marking an increase of 10.27%[22] - The company experienced a 120.58% increase in current liabilities due to new long-term borrowings[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,647[14] - The largest shareholder, Changsha Medical, holds 40.66% of shares, totaling 85,079,923 shares, with 8,010,000 shares pledged[14] - The company plans to repurchase shares at a price not exceeding RMB 53.00 per share, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million[17] - As of March 31, 2024, the company has repurchased 903,600 shares, accounting for 0.43% of the total share capital, with a total transaction amount of RMB 29,392,129.55[17] - The company has approved a restricted stock incentive plan, granting a total of 6,633,000 shares, which is approximately 3.17% of the total share capital[18] - The first grant of restricted stock is set at a price of RMB 16.60 per share, with the first grant date on March 21, 2024[18] - The company has a total of 209,238,250 shares outstanding[17] Other Financial Metrics - The company's cash and cash equivalents at the end of the reporting period amount to RMB 1,749,183,129.15, an increase from RMB 1,569,426,398.74 at the beginning of the period[19] - The company's accounts receivable stand at RMB 475,512,595.40, slightly up from RMB 474,095,353.97 at the beginning of the period[19] - Research and development expenses decreased to CNY 22.37 million in Q1 2024 from CNY 29.50 million in Q1 2023, a decline of 24.16%[23] - The company did not report any new strategies or product developments during this quarter[8] - The company did not report any net profit from the merged entity prior to the merger, with previous net profit also reported as 0[26]
可孚医疗(301087) - 2024 Q1 - 季度财报